Bristol Myers Squibb
The Associate Director of Strategic Accounts will optimize access and appropriate utilization of ORENCIA IV (abatacept) and SOTYKTU (Deucravacitinib), while elevating BMS as a leader within Immunology with National Organized Rheumatology and Dermatology Networks, Infusion Management Companies, Rheumatology Management Service Organizations, Private Equity-owned groups and large independent, and consolidated group practices. This role involves developing and executing strategic initiatives, understanding clinical, economic, and formulary dynamics, and working cross-functionally with internal stakeholders.